| Literature DB >> 35513485 |
Michele Wieczorek1, Sara Mariotto2, Sergio Ferrari2, Federico Mosna3, Maria Caterina Micò4, Carlo Borghero5, Maria Vittoria Dubbini6, Michele Malagola7, Cristina Skert8, Angelo Andreini1, Beatrice De Marco1, Diana Polo2, Ahmad Tfaily9, Mauro Krampera1, Anna Grassi4, Anna Candoni6, Federica Ranzato10, Irene Volonghi11, Rocco Quatrale12, Fabio Benedetti1, Cristina Tecchio13.
Abstract
Neurological complications (NCs) represent a diagnostic and clinical challenge in allogeneic hematopoietic stem cell transplant (alloHSCT) patients. We retrospectively analyzed NC incidence, etiology, timing, characteristics, outcome, and long-term effects in 2384 adult patients transplanted in seven Italian institutions between January 2007 and December 2019. Ninety-three (3.9%) patients were affected by 96 NCs that were infectious (29.2%), immune/inflammatory (26%), drug-related (12.5%), cerebrovascular (5.2%), metabolic (3.1%), related to central nervous system disease relapse (11.5%) and malignancy (3.1%), or undefined (9.4%). Six patients (6.4%) had neurological manifestations of chronic graft-versus-host disease (GVHD). NCs occurred on average at day +128 (from -5 to +4063). Early (< day +120) and late NCs had similar frequencies (46.9% vs 53.1%, p = 0.39). Thirty-one patients (33.3%) were affected by acute or chronic GVHD at the NC onset. With a median follow-up of 25.4 (0.4-163) months, the overall mortality due to NCs was 22.6%. The median time between NC onset and death was 36 (1-269) days. Infectious NCs were the main cause (61.9%) of NC-related mortality. A persistent neurological impairment occurred in 20.4% patients, 57.9% of whom being affected by immune/inflammatory NCs. This study highlights the rare, yet severe impact of alloHSCT-associated NCs on patient survival and long-term functional ability.Entities:
Mesh:
Year: 2022 PMID: 35513485 DOI: 10.1038/s41409-022-01690-x
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.174